Calculate your potential savings with our ROI Calculator
ROI Calculator
To begin with, before jumping into any detail, let's take the example of Peter, who operates a laboratory and a manufacturing plant in the diagnostic space that used to have a predictable workflow until a few years ago. His team would design an assay, verify its basic performance, and bring it to the European market under a simple self-declaration framework. Now, that's an old way of doing things; those days are gone. Peter has to change his approach now to stay relevant to the changing demands of the regulatory environment.
The European diagnostic sector is currently navigating the most profound regulatory shake-up in its history; the European Union In Vitro Diagnostic Medical Devices Regulation (EU IVDR) which came into force in 2017 has now become the only applicable regulation from 2025; this has fundamentally rewritten the rules for bringing diagnostic tools to Europe.
This blog provides a detailed look at the regulation, its structural demands, and how to protect your market access.
The In Vitro Diagnostic Medical Devices Regulation, formally known as Regulation (EU) 2017/746, is the binding legal framework governing all diagnostic products placed on the European market. It sets rigorous standards for safety, clinical performance, and traceability.
The IVDR replaces the old In Vitro Diagnostic Directive (IVDD 98/79/EC) from the late 1990s, because the IVDD was a directive and individual European countries interpreted the text into local laws, leading to fragmented enforcement. The old system of IVDD also allowed roughly 80%-90% of diagnostics to enter the market through simple self-certification with zero independent oversight. Gradually, high-profile product failures and the rapid rise of complex genetic sequencing tools forced European authorities to overhaul the system completely.
The primary objective of the IVDR is to create a seamless, transparent, and secure environment for diagnostics by focusing on three main areas:
To actually understand the shift from the old directive to the new regulation, it is crucial to identify gaps in your current documentation. Now, as a regulation, the IVDR is immediately legally binding across all EU member states; this eliminates regional variations that used to complicate European distribution strategies.
The compliance burden has expanded significantly, and the IVDR requires active, living compliance folders updated continuously based on field performance data. Also, the new regulation demands actual clinical performance evidence, and you must prove your test works in real-world environments on real patient populations, matching the exact claims made on your labels plus your submitted report.
On the contrary, under the old directive, only a tiny fraction of devices required independent auditing before launching; the IVDR reverses this structure entirely.
The below simplified table throws ample light on the difference between the IVDD and the IVDR:
| Feature | IVDD (Old Directive) | IVDR (Current Regulation) |
| Type of Legislation | Directive: Had to be transposed into each EU country's national law, leading to local variations. | Regulation: Applies directly and identically to all EU member states without national tweaks. |
| Risk Classification | List-based: Devices were categorized based on specific lists (List A, List B, Self-Certified). | Rule-based: Classifies devices from Class A (lowest risk) to Class D (highest risk) using specific rules. |
| Notified Body Involvement | Only about 10% to 20% of IVDs required a Notified Body audit. Most were self-certified. | Over 80% to 90% of IVDs now require independent oversight by a Notified Body. |
| Clinical Evidence | Requirements were relatively vague and less stringent. | Highly strict requirements for continuous clinical performance studies and data. |
| Traceability | No centralized tracking system for devices. | Requires a UDI (Unique Device Identifier) for every product, registered in the EUDAMED database. |
| Responsible Person | No formal requirement for a dedicated regulatory expert. | Manufacturers must appoint a PRRC (Person Responsible for Regulatory Compliance). |
The definition of an in vitro diagnostic tool has been widened under the new regulation, dragging several modern digital applications into the regulatory net for the first time.
Under the IVDR, an In Vitro Diagnostic (IVD) medical device is generally defined as any reagent, product, kit, instrument, or system intended to be used in vitro (outside the living body) for examining specimens derived from the human body.
Below are the specific types of products that qualify as IVDs:
Examples of Qualifying Products by Purpose
To qualify as an IVD, the product must be intended to provide information concerning:
Well, several specialized categories face increased scrutiny under this expanded scope:
Now that we have understood the scope of the IVDR and the products that qualify as IVDs, let's look at the device classification. The IVDR brings a new approach to the classification and deliberately abandons the old arbitrary list-based system in favor of a logical, risk-based classification model. In the current state of things, the framework utilizes seven specific rules outlined in Annex VIII to sort products into four distinct categories or class to be more appropriate based on the consequences of an incorrect test result. Here it goes:
You probably already know that to sell a diagnostic product in Europe, you must construct a comprehensive regulatory framework that covers the entire lifecycle of the device. This usually starts with the General Safety and Performance Requirements (GSPR) found in Annex I, which replace the old Essential Requirements checklist with a new rigorous collection of criteria covering chemical, mechanical, and labeling safety.
Manufacturers must also establish a continuous performance evaluation process which requires collecting data across three distinct pillars:
Compliance is no longer, as a matter of fact, a static milestone achieved before just before the launch, manufacturers must build active Post-Market Surveillance (PMS) systems as well to gather safety data from actual users, which feeds back into your risk documents. All of this information must be compiled into exhaustive, organized technical documentation files that are readily accessible for regulatory review.
We know the pros of proving that a diagnostic test provides a real medical benefit, it is a core demand of the new regulation, requiring three distinct forms of evidence compiled into a single, comprehensive document known as the Performance Evaluation Report (PER).
The move towards independent auditing has placed Notified Bodies at the center of the European diagnostic market, indirectly creating significant operational logjams for manufacturers; because the classification rules changed, hundreds of companies that used to launch products via self-declaration must now pass through a formal audit.
The pathway to certification follows a structured process:
The industry is currently facing a massive capacity crunch, there are simply not enough designated Notified Bodies available to handle the global volume of diagnostic tests transitioning to the new system, which frequently pushes review timelines out to 18 or 24 months.
It is obvious that the sudden implementation of such big and impactful changes could be detrimental; hence, to prevent widespread shortages of critical diagnostic tests across European hospitals, authorities stepped in to extend original implementation timelines through Regulation (EU) 2024/1860.
These extended deadlines apply only to legacy products that continue to comply with the old directive, avoid any significant design changes, and maintain an active, IVDR-compliant QMS. The extended market windows are split across risk tiers:
To reap the benefits of these concessions and to access these grace periods, manufacturers must hit a critical milestone; you must lodge a formal application for conformity assessment with a Notified Body by specific dates. For example, for legacy Class C diagnostics, the drop-dead date to lodge an application is May 26, 2026, with a formal signed contract required by September 26, 2026. Missing these dates means you lose the grace period entirely.
So far, one thing you must have realized is that traceability is a central pillar of the new regulation, requiring manufacturers to integrate their supply chains with a centralized European database. Unique Device Identification (UDI) requires that every diagnostic product carries a specialized barcode or data matrix on its label, splitting into a Device Identifier (UDI-DI) for company/model tracking and a Production Identifier (UDI-PI) for lot and batch numbers.
Next, this information syncs directly with EUDAMED (the European Database on Medical Devices). EUDAMED brings together data across six interconnected modules, covering economic operator registration, device tracking, certificates, notified bodies, clinical studies, and vigilance; while following recent updates, individual modules are being rolled out gradually as they pass independent audits, making compliance mandatory as each piece goes live.
Below is a table for your better understanding of the terms:
| Requirement Area | Key Obligations & Details |
| Basic UDI-DI | The primary identifier for a device model; it connects the device to the technical documentation and EC declaration of conformity before placing it on the market. |
| UDI-DI & UDI-PI |
UDI-DI: Static identifier for the specific device version/model.
UDI-PI: Dynamic identifier capturing production data (e.g., lot/batch number, expiry date). |
| UDI Carrier | The combination of UDI-DI and UDI-PI must be placed on the device label and/or outer packaging in both Human Readable Interpretation (HRI) and Automatic Identification and Data Capture (AIDC/barcode) formats. |
| EUDAMED Registration | Manufacturers, Authorized Representatives, and Importers must register as Actors; devices and their associated UDI data must be uploaded to the EUDAMED database. |
| Timelines & Compliance | Phased deadlines based on device risk class; higher-risk devices (Class D) require immediate compliance, while lower-risk classes have extended transition periods. |
The regulation treats quality assurance as a continuous cycle that tracks devices throughout their commercial lifetimes. So, to implement and bring this into standard practice manufacturers must author a detailed Post-Market Surveillance Plan for every product family, summarizing findings into specific reports depending on device classification:
When any serious incidents happen, they must be reported instantly through the vigilance system within 15 days of your team identifying the event. Additionally, manufacturers must use post-market performance follow-up (PMPF) to proactively collect clinical data via user surveys or laboratory records, to ensure that emerging mutations or population shifts do not compromise assay accuracy over time.
Every big change comes with its own set of challenges and transitioning to this new regulatory framework presents steep operational challenges for diagnostic firms across the globe, typically centering on a few critical pain points:
The old way of working on the paper charts and local folders risks your market access and the solution lies in investing into a modern, AI-Powered Quality Management System (QMS) that provides the automation that digital infrastructure needs to maintain compliance and pass audits under pressure.
It is important to transition to a digital QMS to eliminate manual compliance gaps, protect your market access, and ensure your team effortlessly hits critical IVDR regulatory milestones.
To move your product catalog successfully through the validation process it requires a systematic, disciplined approach:
If there is a compliance requirement, there must be a consequence too for non-compliance. Let’s jump into the consequences of ignoring transition timelines or failing a conformity assessment; well, the penalties are severe which can directly threaten your corporate survival. To begin with, missing a transitional milestone renders your CE certificate invalid, leading to immediate market access restrictions that halt European shipments and cut off regional revenue streams.
Regulators can also order the immediate withdrawal of non-compliant diagnostics from laboratory shelves through forced product recalls, which require your team to manage complex logistics and absorb the cost of scrapped inventory. Furthermore, national competent authorities can issue public warning notices or freeze manufacturing operations and these regulatory enforcement actions create massive financial and reputational risks, allowing competitors to quickly step in and fill the supply gap.
The diagnostic regulatory ecosystem will continue to adapt as clinical technology evolves, the use of artificial intelligence to screen tissue samples or predict disease pathways is drawing intense scrutiny from European authorities, who are developing specialized AI and digital diagnostics considerations to evaluate adaptive software models. This also matches a broader global movement toward increasing regulatory harmonization, signaling that thorough documentation built for Europe will simplify registration tasks in other global regions.
According to Gartner’s Strategic Tech Trends report, organizations are beginning to see evolving expectations for diagnostic manufacturers regarding autonomous digital channels. By 2028, over half of generative AI applications used at enterprise service levels will require domain-specific language models (DSLMs) to manage accuracy, context, and compliance. For diagnostic firms, this simply means your internal verification processes must adapt to audit automated content creation to preserve absolute data integrity.
We have understood that transitioning to the EU IVDR is a complex, resource-intensive journey that tests the operational discipline of any diagnostic firm, but by using a structured risk classification approach, securing your clinical evidence early, and utilizing digital quality systems to manage the documentation load, you can secure your access to the European market. Always remember that true compliance is not about survival; it is about building a rock-solid quality program that protects the safety and trust of the patients who rely on your diagnostic insights every single day.
Author
Qualityze Editorial is the unified voice of Qualityze, sharing expert insights on quality excellence, regulatory compliance, and enterprise digitalization. Backed by deep industry expertise, our content empowers life sciences and regulated organizations to navigate complex regulations, optimize quality systems, and achieve operational excellence.
